News
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks.
Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.
1d
Zacks Investment Research on MSNHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...
Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...
8d
Zacks Investment Research on MSNEli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results